MCID: PLM014
MIFTS: 52

Pleomorphic Adenoma malady

Categories: Cancer diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Pleomorphic Adenoma

Aliases & Descriptions for Pleomorphic Adenoma:

Name: Pleomorphic Adenoma 12 14
Mixed Tumor, Not Otherwise Specified 69
Mixed Tumor of the Salivary Gland 12
Mixed Salivary Gland Tumor 69
Adenoma, Pleomorphic 42
Adenoma Pleomorphic 52

Classifications:



External Ids:

Disease Ontology 12 DOID:452
MeSH 42 D008949
NCIt 47 C35691 C8602
SNOMED-CT 64 8360001
UMLS 69 C0026277

Summaries for Pleomorphic Adenoma

Disease Ontology : 12 A gastrointestinal benign neoplasm that is a located in the salivary glands.

MalaCards based summary : Pleomorphic Adenoma, also known as mixed tumor, not otherwise specified, is related to mesenchymoma and pleomorphic adenoma carcinoma. An important gene associated with Pleomorphic Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Development ERBB-family signaling and DNA Damage. The drugs Carboplatin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Wikipedia : 71 Pleomorphic adenoma is a common benign salivary gland neoplasm characterised by neoplastic proliferation... more...

Related Diseases for Pleomorphic Adenoma

Diseases related to Pleomorphic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
id Related Disease Score Top Affiliating Genes
1 mesenchymoma 29.7 MUC1 TP63 VIM
2 pleomorphic adenoma carcinoma 12.3
3 adenoma 11.1
4 mixed lacrimal gland cancer 11.1
5 adenomas, salivary gland pleomorphic 10.9
6 liver fibrosarcoma 10.3 GFAP TP53
7 lupus - neurological sequelae 10.3 S100B VIM
8 cervical adenoid cystic carcinoma 10.3 GFAP TP53
9 lucey-driscoll syndrome 10.3 MUC1 S100B
10 secondary pulmonary hemosiderosis 10.3 MUC1 S100B
11 adenoiditis 10.3
12 myoepithelial carcinoma 10.3
13 benign schwannoma 10.3 S100B VIM
14 adult brainstem gliosarcoma 10.3 GFAP TP53 VIM
15 lymphomatoid papulosis 10.3 ACTC1 VIM
16 invasive mole 10.3 MUC1 S100B
17 bronchitis 10.3 GFAP TP53
18 bile duct clear cell adenocarcinoma 10.3 GFAP TP53
19 vesicoureteral reflux 3 10.3 HMGA2 PLAG1 S100B
20 chest wall parachordoma 10.3 ACTC1 VIM
21 cystinosis, nephropathic 10.3 ERBB2 TP53
22 central nervous system mature teratoma 10.3 ERBB2 S100B TP53
23 arthus reaction 10.3 ERBB2 GFAP TP53
24 skin glomus tumor 10.2 GFAP S100B VIM
25 adenocarcinoma 10.2
26 endometrial stromal sarcoma 10.2 GFAP MUC1 VIM
27 lung clear cell-sugar-tumor 10.2 ERBB2 TP53
28 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 10.2 MUC1 S100B VIM
29 subglottis verrucous carcinoma 10.2 MUC1 S100B VIM
30 inner ear cancer 10.2 GFAP S100B TP53
31 clear cell ependymoma 10.2 MUC1 S100B VIM
32 angiofollicular lymph hyperplasia 10.2 ACTC1 GFAP
33 pericardium leiomyoma 10.2 ACTC1 TP53
34 c-p angle neurinoma 10.2 GFAP S100B VIM
35 myelinoclastic diffuse sclerosis 10.2 GFAP MUC1 S100B
36 ovarian cystadenoma 10.2 GFAP MUC1 S100B
37 trombiculiasis 10.2 GFAP MUC1 S100B
38 kidney benign neoplasm 10.2 MUC1 TP53 VIM
39 acute generalized exanthematous pustulosis 10.2 ACTC1 S100B
40 human granulocytic anaplasmosis 10.2 MUC1 TP53 VIM
41 isolated anterior cervical hypertrichosis 10.2 ACTC1 VIM
42 rommen mueller sybert syndrome 10.2 MDM2 TP53
43 estrogen-receptor positive breast cancer 10.2 ERBB2 KRT14 TP53
44 mucoepidermoid carcinoma 10.2
45 vestibular gland benign neoplasm 10.2 HMGA2 PLAG1 TP53
46 bronchial mucus gland adenoma 10.2 GFAP S100B
47 subependymal glioma 10.2 KRT14 MUC1 VIM
48 dental caries 10.2 ERBB2 MUC1 TP53
49 nasal cavity disease 10.2 ERBB2 MUC1 TP53
50 glomangioma 10.2 ACTC1 TP53 VIM

Graphical network of the top 20 diseases related to Pleomorphic Adenoma:



Diseases related to Pleomorphic Adenoma

Symptoms & Phenotypes for Pleomorphic Adenoma

GenomeRNAi Phenotypes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 S100B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.84 VIM
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.84 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.84 PLAG1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.84 PLAGL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.84 VIM PLAGL2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.84 PLAG1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.84 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.84 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.84 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.84 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.84 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.84 VIM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.84 ERBB2 PLAG1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.84 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.84 PLAG1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.84 ERBB2 PLAG1 PLAGL2 S100B VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 PLAGL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 PLAGL2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 VIM ERBB2 S100B
25 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.84 PLAG1

MGI Mouse Phenotypes related to Pleomorphic Adenoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 ACTC1 AR ERBB2 GFAP KRT14 MDM2
2 growth/size/body region MP:0005378 10.23 ACTC1 AR ERBB2 GFAP KRT14 MDM2
3 cardiovascular system MP:0005385 10.19 ACTC1 AR ERBB2 GFAP MDM2 PLAGL1
4 homeostasis/metabolism MP:0005376 10.17 ACTC1 AR ERBB2 GFAP KRT14 MDM2
5 embryo MP:0005380 10.13 AR ERBB2 MDM2 PLAG1 PLAGL1 SERPINB5
6 digestive/alimentary MP:0005381 10.1 KRT14 MDM2 PLAGL2 TP53 TP63 AR
7 mortality/aging MP:0010768 10.1 ACTC1 AR ERBB2 GFAP KRT14 MDM2
8 integument MP:0010771 10.01 S100B TP53 TP63 AR ERBB2 KRT14
9 craniofacial MP:0005382 9.99 AR ERBB2 KRT14 MDM2 TP53 TP63
10 muscle MP:0005369 9.86 VIM MDM2 TP53 TP63 ACTC1 AR
11 limbs/digits/tail MP:0005371 9.85 ERBB2 MDM2 PLAGL1 TP53 TP63 AR
12 neoplasm MP:0002006 9.63 AR ERBB2 KRT14 MDM2 TP53 TP63
13 normal MP:0002873 9.61 ACTC1 AR ERBB2 GFAP MDM2 S100B
14 reproductive system MP:0005389 9.23 TP53 TP63 VIM AR ERBB2 KRT14

Drugs & Therapeutics for Pleomorphic Adenoma

Drugs for Pleomorphic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
6 Alkylating Agents Phase 3,Phase 2
7 Antimitotic Agents Phase 3,Phase 2,Phase 1
8 Antineoplastic Agents, Alkylating Phase 3,Phase 2
9 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
10 Isophosphamide mustard Phase 3,Phase 2
11
Gemcitabine Approved Phase 2 95058-81-4 60750
12
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
13
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
14
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
15
Mesna Approved Phase 2 3375-50-6 598
16
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
17
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
18
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
19
Metformin Approved Phase 2 657-24-9 14219 4091
20
nivolumab Approved Phase 2 946414-94-4
21
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
22
Everolimus Approved Phase 2 159351-69-6 6442177
23
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
24
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
25
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
27
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
28
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
29
Doxil Approved June 1999 Phase 2 31703
30
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
31
Epothilone B Experimental, Investigational Phase 2 152044-54-7
32 Anti-Infective Agents Phase 2
33 Antimetabolites Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 2,Phase 1
35 Antiviral Agents Phase 2
36 Immunosuppressive Agents Phase 2,Phase 1
37 Angiogenesis Inhibitors Phase 2,Phase 1
38 Angiogenesis Modulating Agents Phase 2,Phase 1
39 Protein Kinase Inhibitors Phase 2,Phase 1
40 Epothilones Phase 2,Phase 1
41 Anti-Bacterial Agents Phase 2
42 Antibiotics, Antitubercular Phase 2
43 Topoisomerase Inhibitors Phase 2
44
iniparib Phase 2
45 Poly(ADP-ribose) Polymerase Inhibitors Phase 2,Phase 1
46 Imatinib Mesylate Phase 2 123596
47 Micronutrients Phase 2
48 Nicotinic Acids Phase 2
49 Trace Elements Phase 2
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show all 48)
id Name Status NCT ID Phase
1 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
2 Quadrant Versus Superficial Parotidectomy Withdrawn NCT01607866 Phase 2, Phase 3
3 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2
4 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Unknown status NCT00511992 Phase 2
5 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2
6 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2
7 Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours Completed NCT00189410 Phase 2
8 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2
9 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
10 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2
11 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2
12 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2
13 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2
14 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2
15 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2
16 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2
17 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2
18 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
19 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
20 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2
21 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2
22 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2
23 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Recruiting NCT01935934 Phase 2
24 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
25 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
26 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Active, not recruiting NCT01168232 Phase 2
27 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2
28 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
29 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2
30 Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer Terminated NCT00322881 Phase 2
31 Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy Terminated NCT00505492 Phase 2
32 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2
33 Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Withdrawn NCT00984217 Phase 2
34 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1
35 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1
36 Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00413075 Phase 1
37 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1
38 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1
39 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Recruiting NCT01991808 Phase 1
40 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1
41 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1
42 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Unknown status NCT01367301
43 Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer Recruiting NCT02983279
44 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT01440998
45 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Active, not recruiting NCT01080521
46 Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection Not yet recruiting NCT02851693
47 microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer Not yet recruiting NCT02964351
48 Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient No longer available NCT02090127

Search NIH Clinical Center for Pleomorphic Adenoma

Cochrane evidence based reviews: adenoma, pleomorphic

Genetic Tests for Pleomorphic Adenoma

Anatomical Context for Pleomorphic Adenoma

MalaCards organs/tissues related to Pleomorphic Adenoma:

39
Salivary Gland, Breast, Bone, Trachea, Tongue, Lung, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Pleomorphic Adenoma:

18
The Salivary Gl

Publications for Pleomorphic Adenoma

Articles related to Pleomorphic Adenoma:

(show top 50) (show all 763)
id Title Authors Year
1
Diffusion-weighted MRI for differentiation between sialadenitis and pleomorphic adenoma. ( 27845594 )
2017
2
Hemifacial Spasm Secondary to Parotid Pleomorphic Adenoma With Stylomastoid Foramen Extension. ( 27755360 )
2017
3
Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/I^-catenin signaling pathway in human colorectal adenocarcinoma. ( 28259923 )
2017
4
Synchronous contralateral pleomorphic adenoma of the parotid gland and submandibular gland. ( 27914682 )
2017
5
Diagnosis of a rapidly growing preauricular nodule: chondroid syringoma or pleomorphic adenoma? ( 27874890 )
2016
6
Genomic profile of a squamous cell carcinoma ex pleomorphic adenoma compared to a head and neck squamous cell carcinoma. ( 26971044 )
2016
7
Loss Expression of Plag1 in Malignant Transformation from Pleomorphic Adenoma to Carcinoma Ex-Pleomorphic Adenoma. ( 27473265 )
2016
8
Carcinoma Ex Pleomorphic Adenoma of the Lacrimal Gland with Epithelial-Myoepithelial Carcinoma Histologic Type. ( 26934566 )
2016
9
Pleomorphic adenoma in the nasal cavity: a clinicopathological study of ten cases in Finland. ( 27056196 )
2016
10
Giant parotid pleomorphic adenoma in a Nigerian male. ( 27538561 )
2016
11
Metastasizing pleomorphic adenoma in cavernous sinus: letter to the editor. ( 26917421 )
2016
12
MYB expression: Potential role in separating adenoid cystic carcinoma (ACC) from pleomorphic adenoma (PA). ( 27491495 )
2016
13
PLAG1: An Immunohistochemical Marker with Limited Utility in Separating Pleomorphic Adenoma from Other Basaloid Salivary Gland Tumors. ( 27463119 )
2016
14
Differing Lymphatic Vessels Density in Salivary Adenoid Cystic Carcinoma and Pleomorphic Adenoma. ( 27837476 )
2016
15
A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases. ( 27423271 )
2016
16
Pleomorphic Adenoma of Minor Salivary Gland Arising de novo in the Parapharyngeal Space- A Rare Case Report. ( 27135010 )
2016
17
Stationary facial nerve paresis after surgery for recurrent parotid pleomorphic adenoma: a follow-up study of 219 cases in Denmark in the period 1985-2012. ( 26869475 )
2016
18
Comparison of Frey Syndrome Rates Following Superficial Parotidectomy and Partial Superficial Parotidectomy for Pleomorphic Adenoma. ( 27391515 )
2016
19
Electrical stimulation treatment for facial palsy after revision pleomorphic adenoma surgery. ( 27106613 )
2016
20
Carcinoma ex-pleomorphic adenoma derived from recurrent pleomorphic adenoma shows important difference by array CGH compared to recurrent pleomorphic adenoma without malignant transformation. ( 26971045 )
2016
21
The relationship between proteoglycan inhibition via xylosyltransferase II silencing and the implantation of salivary pleomorphic adenoma. ( 27732748 )
2016
22
Re: Differentiation of pleomorphic adenoma and Warthin's tumour of theA salivary gland: is long-to-short ratio a useful parameter? ( 26874659 )
2016
23
Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma. ( 28012286 )
2016
24
Twist Expression in Pleomorphic Adenoma, Adenoid Cystic Carcinoma and Mucoepidermoid Carcinoma of Salivary Glands. ( 26832177 )
2016
25
Pleomorphic adenoma of a deep orbital ectopic lacrimal gland. ( 27541944 )
2016
26
Pleomorphic adenoma rehabilitative treatment in growing up patient: a 20-years follow-up. ( 27649650 )
2016
27
Pleomorphic adenoma of the larynx. ( 28058389 )
2016
28
Rare Primary Pleomorphic Adenoma in Posterior Fossa. ( 27465421 )
2016
29
Pleomorphic Adenoma of the Larynx: A Case Report. ( 26878007 )
2016
30
Recurrent pleomorphic adenoma of the parotid gland: Institutional experience and review of the literature. ( 27468730 )
2016
31
Minimally invasive carcinosarcoma ex pleomorphic adenoma: A case report and literature review with cytohistological correlation. ( 27080524 )
2016
32
Rare Carcinoma Ex-pleomorphic Adenoma of Buccal Mucosa: Case Report and Review of Literature. ( 27134712 )
2016
33
Thoracic intramedullary spinal metastasis from carcinoma ex pleomorphic adenoma of the submandibular gland. ( 27841228 )
2016
34
Incidentally Detected Carcinoma Ex Pleomorphic Adenoma of Parotid Gland by F-18 FDG PET/CT. ( 26941868 )
2016
35
Pedunculated carcinoma ex pleomorphic adenoma of the nasal cavity: A unique case report. ( 27684860 )
2016
36
Comparison of functional change in parotid gland after surgical excision of pleomorphic adenoma by two different types of parotidectomy. ( 27492567 )
2016
37
Pleomorphic adenoma involving soft tissue overlying the anterior border of ramus of the mandible: A rare ectopic presentation. ( 27900254 )
2016
38
Clinico-radiological features of primary lacrimal gland pleomorphic adenoma: an analysis of 37 cases. ( 27184391 )
2016
39
Carcinoma Ex Pleomorphic Adenoma of the Tongue: Difficulty in Diagnosis Between Metastasis of Breast Cancer and Salivary Tumor. ( 27755404 )
2016
40
Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer. ( 27537362 )
2016
41
Invasive myoepithelial carcinoma ex pleomorphic adenoma of the major salivary gland: two case reports. ( 27793123 )
2016
42
Pleomorphic adenoma and adenoid cystic carcinoma of salivary glands: E-cadherin immunoexpression and analysis of the CDH1 -160C/A polymorphism. ( 27665273 )
2016
43
Endobronchial pleomorphic adenoma. ( 28031854 )
2016
44
Pleomorphic Adenoma in Retromolar Area: A Very Rare Case Report and Review of Literature. ( 26894184 )
2016
45
Combined salivary duct carcinoma and squamous cell carcinoma suspected of carcinoma ex pleomorphic adenoma. ( 27435055 )
2016
46
Prognostic factors of carcinoma ex pleomorphic adenoma of the salivary glands, with emphasis on the widely invasive carcinoma: a clinicopathologic analysis of 361 cases in a Chinese population. ( 27546212 )
2016
47
Unusual Pleomorphic Adenoma of the Lacrimal Gland: Immunohistochemical Demonstration of PLAG1 and HMGA2 Oncoproteins. ( 27567603 )
2016
48
Carcinoma Ex Pleomorphic Adenoma: Is It a High-Grade Malignancy? ( 27131030 )
2016
49
Oncocytic Pleomorphic Adenoma of Palatal Salivary Gland with Macrophages and Giant Cells Associated with Cholesterol Crystals. ( 28028431 )
2016
50
Giant pleomorphic adenoma of the parotid gland. ( 27061390 )
2016

Variations for Pleomorphic Adenoma

Cosmic variations for Pleomorphic Adenoma:

9 (show all 12)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43909 TP53 salivary gland,parotid,adenoma,pleomorphic c.817C>A p.R273S 15
2 COSM10808 TP53 salivary gland,parotid,adenoma,pleomorphic c.488A>G p.Y163C 15
3 COSM44733 TP53 salivary gland,NS,adenoma,pleomorphic c.698A>C p.H233P 14
4 COSM43878 TP53 salivary gland,NS,adenoma,pleomorphic c.427G>A p.V143M 14
5 COSM533 KRAS salivary gland,NS,adenoma,pleomorphic c.38G>C p.G13A 14
6 COSM482 HRAS salivary gland,NS,adenoma,pleomorphic c.34G>C p.G12R 14
7 COSM486 HRAS salivary gland,NS,adenoma,pleomorphic c.37G>C p.G13R 14
8 COSM480 HRAS salivary gland,NS,adenoma,pleomorphic c.34G>A p.G12S 14
9 COSM43635 TP53 salivary gland,parotid,adenoma,myoepithelial c.536A>T p.H179L 11
10 COSM6932 TP53 salivary gland,parotid,adenoma,myoepithelial c.733G>A p.G245S 11
11 COSM13168 CTNNB1 salivary gland,parotid,adenoma,NS c.104T>C p.I35T 10
12 COSM5688 CTNNB1 salivary gland,parotid,adenoma,NS c.121A>C p.T41P 10

Copy number variations for Pleomorphic Adenoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 239266 8 38279166 38315052 Gain FGFR1 Pleomorphic adenoma

Expression for Pleomorphic Adenoma

Search GEO for disease gene expression data for Pleomorphic Adenoma.

Pathways for Pleomorphic Adenoma

GO Terms for Pleomorphic Adenoma

Cellular components related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.73 ACTC1 AR ERBB2 GFAP KRT14 MDM2
2 nuclear chromatin GO:0000790 8.92 AR MUC1 TP53 TP63

Biological processes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.91 AR HMGA2 PLAG1 PLAGL1 PLAGL2 TP53
2 negative regulation of apoptotic process GO:0043066 9.85 ACTC1 HMGA2 MDM2 TP53 TP63
3 cell proliferation GO:0008283 9.8 AR ERBB2 HMGA2 S100B TP53
4 transcription from RNA polymerase II promoter GO:0006366 9.73 HMGA2 PLAG1 PLAGL1 PLAGL2 TP53 TP63
5 cellular response to hypoxia GO:0071456 9.71 MDM2 S100B TP53
6 epithelial cell differentiation GO:0030855 9.65 KRT14 MUC1 TP63
7 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.52 AR ERBB2
8 mitotic G1 DNA damage checkpoint GO:0031571 9.51 TP53 TP63
9 prostate gland development GO:0030850 9.49 AR TP63
10 prostate gland growth GO:0060736 9.43 AR PLAG1
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.33 MUC1 TP53 TP63
12 cellular response to actinomycin D GO:0072717 9.32 MDM2 TP53
13 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.26 MDM2 MUC1 PLAGL1 TP53
14 positive regulation of gene expression GO:0010628 9.23 ACTC1 AR ERBB2 HMGA2 MDM2 PLAG1

Molecular functions related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.8 AR PLAG1 PLAGL1 PLAGL2 TP53 TP63
2 structural constituent of cytoskeleton GO:0005200 9.58 GFAP KRT14 VIM
3 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.55 AR HMGA2 PLAG1 PLAGL2 TP63
4 identical protein binding GO:0042802 9.5 ERBB2 GFAP MDM2 S100B TP53 TP63
5 transcription factor activity, transcription factor binding GO:0000989 9.37 HMGA2 TP63
6 keratin filament binding GO:1990254 9.26 KRT14 VIM
7 p53 binding GO:0002039 8.92 MDM2 MUC1 TP53 TP63

Sources for Pleomorphic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....